APS and Biomodels form alliance to boost supportive cancer care

This alliance allows speedier product development and helps Applied Protein Sciences (APS) expand its pipeline to develop drugs for mucositis, proctitis and inflammatory bowel disease. APS expects to launch its clinical program later in 2009.

This collaboration is also expected to boost APS efforts to build a technology platform that can be scaled to encompass all aspects of supportive oncology care.

Aman Johar, CEO of APS, said: “We are very excited about partnering with Biomodels. This relationship allows us flexibility to customize our preclinical studies, maintain our clinical end-points and effectively utilize capital resources.

“A full-scale collaboration extends our research platform and provides access to leading scientists and researchers. Biomodels’s proven models reliably predict clinical success in an extremely complex field of mucositis. APS products can be the standard of care for preventing mucositis – saving over $2 billion annually in hospitalization costs.”